The complement C6 test evaluates whether complement component 6 can perform its role in the membrane attack complex, the terminal structure that helps the immune system kill susceptible bacteria. C6 deficiency is rare, but it is clinically important because it can leave a person unusually vulnerable to invasive infections caused by Neisseria meningitidis and, less often, disseminated Neisseria gonorrhoeae. Testing usually begins after recurrent or unusual meningococcal disease or after both CH50 and AH50 are absent despite normal C3 and C4 concentrations.
Most available C6 tests are functional assays rather than routine screening measurements. A low value can reflect inherited C6 deficiency, broad complement consumption, severe protein-production or loss problems, complement-inhibiting therapy, or specimen mishandling. Therefore, one abnormal result must be confirmed and placed into a pathway pattern. This article follows the clinical path from the role of C6 through test selection, interpretation, genetic confirmation, vaccination, and recognition of urgent infection symptoms.
- C6 binds C5b and helps build the membrane attack complex; it is shared by all complement activation pathways.
- Complete C6 deficiency usually makes both CH50 and AH50 undetectable while C3 and C4 may remain normal.
- Functional testing is important because measurable C6 protein can occasionally be ineffective.
- Recurrent invasive meningococcal disease is the strongest clinical clue to a terminal complement defect.
- Vaccination and rapid evaluation of fever reduce risk but cannot provide complete protection.
Table of Contents
- How C6 helps build the membrane attack complex
- Who needs a C6 test and who usually does not
- What the C6 functional result actually shows
- The infection pattern of inherited C6 deficiency
- When low C6 is not an inherited deficiency
- A diagnostic route from CH50/AH50 to genetics
- Building a long-term prevention plan
- Emergency signs and practical questions
How C6 helps build the membrane attack complex
The classical, lectin, and alternative complement pathways begin differently, but all can generate enzymes that cleave C5. C5b, one of the resulting fragments, is unstable unless it quickly binds C6. Once the C5b-C6 complex forms, it recruits C7, inserts into or associates with a target membrane, and then adds C8 and C9. This sequence creates the membrane attack complex, also called MAC or C5b-9.
C6 is not an enzyme. It is a structural component that stabilizes C5b and permits orderly assembly of the terminal complex. Without effective C6, C5b cannot progress normally to a bactericidal pore. Upstream complement functions still operate: antibodies can trigger complement, C3b can coat microbes, and inflammatory fragments such as C3a and C5a may be generated. The specific gap is terminal lysis.
That gap matters most for Neisseria. These gram-negative bacteria are particularly dependent on complement-mediated serum killing. A person lacking C6 can still make antibodies and opsonize organisms, which may explain why the infection phenotype is narrower than in complete C3 deficiency. Nevertheless, meningococcal disease can be severe, recurrent, or caused by strains that are unusual in the general population.
C6 deficiency belongs to the group of terminal complement pathway deficiencies, together with C5, C7, C8, and C9 deficiency. The initial laboratory pattern is similar across the group because CH50 and AH50 both require every shared terminal component. Individual functional tests are needed to identify which protein is missing or defective.
The distinction from early classical-pathway defects is clinically useful. Deficiencies of C1, C2, or C4 impair immune-complex clearance and are strongly associated with lupus-like autoimmunity. Terminal deficiencies are dominated by neisserial infection risk. Autoimmune disease can still occur in an individual with C6 deficiency, but it is not the defining presentation.
C6 should also be separated from soluble C5b-9 testing. Soluble C5b-9 is an activation marker used in selected complement-mediated illnesses. It may be high when terminal complement is overactive. A C6 functional test asks the opposite type of question: can the patient’s C6 support terminal activity?
Who needs a C6 test and who usually does not
C6 testing is a targeted investigation. It is not a general wellness test and is not usually ordered for ordinary respiratory infections, fatigue, a positive ANA, or a mildly low C3 or C4 result.
The strongest indication is recurrent invasive meningococcal disease. A second episode of meningococcal meningitis or bloodstream infection should prompt evaluation for persistent complement deficiency and other predisposing conditions. Testing may also be considered after a first episode when the patient is older than the usual peak age, the infecting serogroup is unusual, there is a family history, or the clinical course suggests an immune defect.
Another indication is disseminated gonococcal infection, especially if recurrent. Gonorrhea ordinarily affects mucosal sites, but terminal complement deficiency can increase susceptibility to spread through the bloodstream, producing fever, migratory joint symptoms, tenosynovitis, skin lesions, or septic arthritis. Sexual exposure and strain factors still matter; the infection is not proof of C6 deficiency.
Laboratory findings can lead to C6 testing even before a characteristic infection. An absent CH50 result together with an absent AH50 result suggests a defect in C3 or a terminal component, severe complement consumption, medication effect, or sample degradation. If C3 and C4 concentrations are normal and the pathway pattern repeats, C5 through C9 testing becomes appropriate.
Family testing is another focused use. Once a relative has genetically and functionally confirmed C6 deficiency, siblings and other relatives at meaningful inheritance risk may be offered testing with genetic counseling. Testing every family member after an unconfirmed low functional result is premature.
C6 testing is generally not useful when CH50 and AH50 are both clearly normal, because intact pathway function argues strongly against complete deficiency. A partial or unusual defect is still possible, but the clinical phenotype must be compelling enough to justify specialized testing.
Testing during acute sepsis can be difficult to interpret because complement is consumed. It can still identify a striking pathway abnormality, but confirmation after recovery is often necessary. Prevention and treatment decisions after meningococcal disease should not wait for the final molecular diagnosis.
What the C6 functional result actually shows
A C6 functional assay measures the ability of C6 in the patient’s serum to support complement-mediated lysis in a controlled system. Laboratories may use C6-deficient reagent serum or another reconstitution design so that patient C6 is the limiting component. The reported value is method-specific and may be expressed in units per milliliter or as a percentage of normal activity.
One current reference laboratory reports a normal threshold of at least 56 U/mL. This is an assay-specific cutoff, not a universal biological boundary. Other laboratories may use a range, a percentage, or qualitative categories. Interpretation must use the reference interval printed on the report.
A result below range can have several meanings:
- Little or no C6 protein is present.
- C6 protein is present but structurally unable to function normally.
- C6 has been consumed as part of broad complement activation.
- A drug or acquired inhibitor is blocking terminal-pathway activity.
- The specimen lost activity before testing.
This is why function is not interpreted alone. If an antigen assay is available, it can distinguish low quantity from dysfunctional protein. However, many clinical workups rely on pathway screens, functional component assays, and genetic testing rather than a widely available C6 antigen concentration.
Specimen handling is especially important. Functional complement proteins deteriorate when serum remains warm too long, is separated late, or undergoes repeated freeze-thaw cycles. The laboratory may require serum to be centrifuged and frozen promptly. A mishandled specimen can make several functional components appear deficient at once.
The test is also affected by complement-targeted medicines. C5 inhibitors prevent the formation of C5b and therefore stop assembly before C6 can act. CH50 and AH50 can be absent even though C6 itself is normal. Panels used to study terminal components should ideally be obtained before such treatment when clinically feasible, and the laboratory must be told about the medication. Treatment should never be paused merely to improve test interpretability without specialist direction.
A normal C6 functional result makes complete C6 deficiency unlikely. It does not exclude deficiencies of C5, C7, C8, or C9, nor does it rule out an infection risk caused by properdin, factor D, or factor H deficiency. The broader pathway pattern determines the next test.
The infection pattern of inherited C6 deficiency
Inherited C6 deficiency is usually autosomal recessive. An affected person has pathogenic variants on both copies of the C6 gene, while parents are often asymptomatic carriers. The exact molecular change can lead to complete absence, markedly reduced activity, or a dysfunctional protein.
The typical presentation is not constant minor illness. It is one or more episodes of significant neisserial disease. Meningococcal meningitis may cause fever, severe headache, neck stiffness, vomiting, light sensitivity, confusion, or seizures. Meningococcemia can cause rapidly progressive sepsis, limb pain, cold extremities, low blood pressure, abnormal breathing, and a non-blanching purple rash. Either syndrome can occur without every textbook feature.
Terminal complement deficiency sometimes produces a paradoxical clinical picture: recurrent disease but a lower case-fatality rate in some historical series compared with complement-sufficient meningococcal disease. Possible explanations include infecting serogroups and preserved antibody/opsonic responses. This observation must never reduce urgency. Any episode can be fatal or cause hearing loss, neurologic injury, scarring, limb loss, or other permanent complications.
Infections may occur in adolescence or adulthood, so the absence of severe childhood infections does not exclude C6 deficiency. Some affected people experience their first recognized episode after entering communal living, military service, university housing, travel to an endemic region, or another setting with increased meningococcal exposure.
Disseminated gonococcal infection is less common but relevant. Symptoms can include fever, pustular skin lesions, tendon-sheath pain, migratory arthritis, or a hot swollen joint. A person may have few genital symptoms. Standard sexual-health evaluation, cultures or nucleic acid testing, and partner management remain necessary.
C6 deficiency does not usually cause low immunoglobulins. If a patient has frequent sinus and lung infections with broadly poor vaccine responses, an antibody deficiency may be more likely or may coexist. A complete immune evaluation should be driven by the full infection history rather than assuming every infection comes from C6.
A documented family history can be subtle. Relatives may remember “meningitis,” sudden death from infection, or recurrent gonococcal complications without knowing the organism or immune diagnosis. Obtaining hospital records or death certificates may clarify whether the pattern fits.
When low C6 is not an inherited deficiency
An acquired low C6 result is more likely when several complement proteins are reduced, the abnormality appears during critical illness, or it resolves after the underlying problem improves.
Complement consumption can occur in severe bacterial infection, immune-complex disease, vasculitis, widespread tissue injury, or complement-mediated blood and kidney disorders. Consumption often lowers CH50 and AH50, but C3 or C4 may also be low. In contrast, isolated inherited C6 deficiency usually leaves upstream antigen concentrations intact.
Advanced liver disease can reduce synthesis of multiple complement proteins. C6 is largely produced in the liver, so severe synthetic failure may lower function. Albumin, coagulation measures, bilirubin, clinical signs, and other complement components help distinguish this broad production problem from selective C6 deficiency.
Protein loss through nephrotic kidney disease, protein-losing enteropathy, extensive burns, or plasma exchange can reduce circulating complement. These conditions typically produce parallel abnormalities in albumin, total protein, immunoglobulins, or other components.
Complement-inhibiting therapy can mimic terminal deficiency in functional assays. Drugs that block C5 cleavage prevent formation of C5b-C6, so C6 cannot be recruited despite being normal. Therapies that inhibit C3 can suppress even more of the cascade. The medication name, last dose, therapeutic target, and assay design are essential interpretive information.
Specimen degradation remains one of the most common correctable explanations for unexpectedly absent functional complement. If several component functions are low without a coherent clinical pattern, repeat testing from a properly handled sample should precede genetic conclusions.
An isolated borderline low C6 function may be difficult to classify. It can represent residual activity from a genetic variant, ordinary assay imprecision near the cutoff, or partial degradation. Clinicians look for reproducibility, family segregation, and compatibility with infection history. A single near-range result should not create a lifelong diagnosis.
A diagnostic route from CH50/AH50 to genetics
A disciplined sequence prevents wasted testing and false labels.
1. Establish the pathway pattern
Order CH50 and AH50 on a correctly handled sample. If both are normal, complete C6 deficiency is unlikely. If CH50 is absent but AH50 is normal, investigate early classical components. If AH50 is absent but CH50 is normal, investigate alternative-pathway factors. If both are absent, move toward C3 and terminal components while considering consumption and treatment.
2. Check upstream concentrations and clinical context
Normal C3 and C4 make an isolated late-component defect more likely. Low C3 and C4 suggest consumption, liver dysfunction, or protein loss. Review acute illness, kidney and liver tests, albumin, medications, plasma products, and sample handling.
3. Localize the terminal defect
Component-specific functional assays for C5, C6, C7, C8, and C9 determine which protein fails to restore activity. Some specialist laboratories use mixing or reconstitution studies. Because every terminal defect can produce the same screening pattern, localization cannot be guessed from CH50/AH50 alone.
| Screening and follow-up pattern | Interpretation |
|---|---|
| CH50 absent, AH50 absent, C6 function absent, other terminal functions preserved | C6 deficiency is strongly supported |
| CH50 absent, AH50 absent, C6 function normal | Look at C3, C5, C7, C8, C9, drug effect, and specimen quality |
| CH50/AH50 low with low C3 and C4 during sepsis | Acquired consumption is more likely than isolated C6 deficiency |
| CH50/AH50 absent during C5-inhibitor therapy | Expected treatment effect; cannot diagnose C6 deficiency from pathway screens |
| Borderline C6 function with normal pathway screens | Complete deficiency is unlikely; repeat or specialist review if phenotype is strong |
4. Repeat before assigning permanence
A second independent specimen reduces the risk of a preanalytical error. Testing after recovery from acute infection may show normalization. If urgency requires decisions sooner, clinicians can institute high-risk vaccination and education while confirmation proceeds.
5. Confirm genetically
Biallelic pathogenic C6 variants can confirm inherited deficiency. Genetic testing may reveal a variant of uncertain significance, so laboratory function and clinical phenotype remain necessary. A molecular result should be interpreted by a clinical immunologist or genetics professional rather than through a direct-to-consumer report.
6. Evaluate relatives selectively
Once the familial variants are known, targeted testing is clearer than broad complement panels. Siblings may be affected or carriers; partners and children have different risks depending on carrier status. Genetic counseling explains these probabilities and avoids confusing carrier-level laboratory values with disease.
Building a long-term prevention plan
A confirmed C6 deficiency changes preventive care even when the person feels completely well. The plan should be documented and reviewed as vaccine recommendations evolve.
Meningococcal vaccination: Current U.S. guidance recommends both MenACWY and MenB vaccination for people with persistent complement component deficiencies. Boosters are required while the increased risk remains. Product choice, number of doses, minimum intervals, and age eligibility vary; a clinician should use the current risk-based schedule rather than the routine adolescent schedule alone. A pentavalent MenABCWY vaccine may be an option when both vaccine categories are due at the same visit in eligible people.
Other immunizations: Pneumococcal vaccination and the full routine schedule should be reviewed. Terminal deficiency is most specifically associated with Neisseria, but preventing other vaccine-preventable infections remains important. Live vaccines are not automatically contraindicated solely because of isolated C6 deficiency, although other health conditions may alter recommendations.
Antibiotic prevention: Some specialists prescribe continuous prophylaxis, particularly after invasive meningococcal disease or when vaccination is incomplete. Others provide an emergency supply with strict instructions. The choice depends on age, prior episodes, local resistance, allergies, access to emergency care, and shared decision-making. Antibiotics do not replace vaccination or emergency assessment.
Education and identification: Carry a medical-alert card or phone record that says “terminal complement deficiency—C6.” Include vaccines, prophylactic medication, allergies, and specialist contact details. Family, school, workplace, and travel companions may need to know when to call emergency services.
Travel and exposure planning: Meningococcal epidemiology differs by region and outbreak. Travel clinics can assess destination-specific vaccines, timing, and access to treatment. Communal living and occupational exposure may require additional planning but should not lead to unnecessary isolation.
Sexual health: Barrier methods, routine screening according to risk, prompt evaluation of symptoms, and partner treatment help prevent gonorrhea and its dissemination. C6 deficiency does not change the need for standard antimicrobial treatment, but clinicians should have a lower threshold to evaluate systemic symptoms.
Vaccination is not perfect in terminal complement deficiency because antibodies rely partly on complement to kill bacteria. The prevention plan therefore combines vaccines with awareness, rapid care, and sometimes antibiotics.
Emergency signs and practical questions
People with C6 deficiency should seek emergency care for fever accompanied by severe headache, neck stiffness, confusion, unusual sleepiness, vomiting, a rapidly spreading non-blanching rash, severe muscle or limb pain, cold hands and feet, breathing changes, or a sense of sudden extreme illness. Do not wait for a rash; meningococcal disease can begin without one. Tell emergency clinicians about the complement deficiency immediately.
A hot swollen joint, fever with scattered pustular skin lesions, or migrating tendon and joint pain also needs prompt evaluation for disseminated gonococcal or other bloodstream infection. Sexual-health information should be shared honestly and confidentially because it changes testing and treatment.
After receiving a low C6 result, useful questions for the ordering clinician include:
- Was this a functional assay, an antigen assay, or part of a panel?
- Were CH50 and AH50 both abnormal on a well-handled sample?
- Were C3 and C4 normal, making an isolated terminal defect more likely?
- Could acute illness, liver disease, protein loss, plasma treatment, or a complement inhibitor explain the result?
- Should testing be repeated after recovery?
- Which vaccines and boosters are due now?
- Is antibiotic prophylaxis appropriate?
- Should relatives receive targeted genetic or functional testing?
Do not interpret the result through the reference number alone. A value below 56 U/mL on one laboratory’s assay is not automatically equivalent to complete deficiency, and another laboratory may use a different method. The diagnosis comes from an absent or reproducibly severe functional defect, the pathway pattern, exclusion of acquired causes, and often genetic confirmation.
The practical value of finding C6 deficiency is substantial. It converts an otherwise unexplained infection history into a prevention strategy and gives patients a reason to seek rapid care for symptoms that others might observe at home. Accurate testing and explicit education are as important as the label itself.
References
- C6 Complement, Functional, Serum. 2026. Laboratory test guidance.
- Risk-based Indications for Meningococcal Vaccination. 2026. U.S. Centers for Disease Control and Prevention guidance.
- Complement deficiencies and infections. 2026. Review article.
- Factors associated with recurrent meningococcal disease. 2024. NICE evidence review.
- Immunodeficiency: Complement disorders. 2024. Clinical review.
- Recurrent meningococcal meningitis with complement 6 (C6) deficiency: A case report. 2020. Case report illustrating C6 deficiency.
Disclaimer
This article provides general educational information and does not replace care from an immunologist, infectious-disease specialist, or other qualified clinician. C6 results depend on assay method, specimen handling, acute illness, and medications and require confirmation in a complete pathway evaluation. Anyone with known or suspected terminal complement deficiency and possible meningococcal symptoms should seek emergency medical care immediately, even after vaccination.
